Week In Review: Yantai's MabPlex Raises $59 Million To Expand CDMO Services

MabPlex, a biologics CDMO, raised $59 million in a Series A round from SDIC Venture Fund and Shenzhen Venture Capital. MabPlex offers biologics development and manufacturing services, including mAbs, recombinant proteins, ADCs and bispecifics.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.